Dr. Abidi Pharmaceutical Laboratories (DABID)
Fundamental analysis of DABID on Fundai: DABID Fundamental Analysis, Mehr 1405: Profit Forecast and Valuation
- Ticker
- DABID
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Line of business
Production, purchase, sale, import and export and carrying out any production and commercial activity; contract manufacturing or manufacturing under license; obtaining agencies from manufacturing, research or supplier companies in relation to all pharmaceutical products, whether chemical, herbal, food and pharmaceutical supplements, special foods, biological and biotechnological products, and medical equipment and supplies
Latest trading day
Date: October 25, 2026
- Closing price
- 26,390 rials
- Change on the previous close
- -2.76%
- Volume
- 28,387,982 shares
- Trade value
- 74.90 billion tomans
- Market cap
- 147,784 billion tomans
DABID returns against the market, the dollar and gold
Up to the stock's last trade on October 25, 2026. Each row runs from the last price before the period starts to the latest price, and the stock's return is adjusted for capital raises and cash dividends. The indexes come from the Tehran Stock Exchange (TSETMC); the free-market dollar and 18k gold are daily free-market prices in tomans.
| Series | 1 month |
|---|---|
| DABID | 1.7% |
| Bourse total index | 12.6% |
| Farabourse total index | 17.1% |
| Free-market dollar | 15.2% |
| 18k gold (per gram) | 7.4% |
Weekly, 3-month, 1-year and 5-year returns, and the comparison with the industry, the Emami gold coin, the world gold ounce and Tehran housing, are on Fundai with free sign-up.
Key figures
| Item | Value | Basis |
|---|---|---|
| P/E TTM | 13.16 | Report to 1405/06/31 |
| P/B | 8.30 | Report to 1405/06/31 |
| Gross margin TTM | 60.9% | Report to 1405/06/31 |
| Net margin TTM | 38.5% | Report to 1405/06/31 |
| ROE TTM | 63.1% | Report to 1405/06/31 |